Trial Profile
A prospective, randomized, two arm, single blind, parallel, active controlled, multicentre, phase II/III clinical study to evaluate the immunogenicity and safety of Inactivated Trivalent Influenza vaccine (split virion) I.P. of M/s Cadila Healthcare Limited compared to marketed Inactivated Trivalent Influenza vaccine in healthy adults
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Zydus Lifesciences
- 02 Sep 2016 New trial record